showed that higher pregnancy-associated protein glycodelin (encoded by the PAEP gene) levels in tumors correlate with significantly worse survival outcomes in female non-small-cell lung cancer (NSCLC) patients treated with immunotherapy, but this was not observed in male patients, suggesting that glycodelin could be used as a promising immunological biomarker to early identify female NSCLC patients who do not benefit from the immunotherapy [35]. The gene discussed is PAEP; the disease is non-small cell lung carcinoma.